Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+) - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-term assessment of safety, tolerability, and effectiveness of subcutaneous efgartigimod PH20 in adults with generalized myasthenia gravis: final findings from the phase 3 open-label extension study (ADAPT-SC+)

  • By

  • Andreas Meisel

  • Carlo Antozzi

  • Ratna Bhavaraju-Sanka

  • Jan L. De Bleecker

  • Wan-Yi Huang

  • Rosa Hermina Jimenez

  • Fien M. Verhamme

  • Ming Jiang

  • Li Liu

  • Denis Korobko

  • Anna Kostera-Pruszczyk

  • Kimiaki Utsugisawa

  • Jan J. G. M. Verschuuren

  • Tuan Vu

  • Heinz Wiendl

  • James F. Howard

  • August 21, 2026

Share

Original Source(s)

Long-term safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in generalized myasthenia gravis: final results from a phase 3 open-label extension study (ADAPT-SC+)

  • by Andreas Meisel, Carlo Antozzi, Ratna Bhavaraju-Sanka, Jan L. De Bleecker, Wan-Yi Huang, Rosa Hermina Jimenez, Fien M. Verhamme, Ming Jiang, Li Liu, Denis Korobko, Anna Kostera-Pruszczyk, Kimiaki Utsugisawa, Jan J. G. M. Verschuuren, Tuan Vu, Heinz Wiendl, James F. Howard

  • August 21, 2026

Related Content

Pediatric neurologist Dr. John Gaitanis to lead NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development

  • August 21, 2026

Retraction: Quantitative GABA magnetic resonance spectroscopy as a measure of motor learning function in the motor cortex after subarachnoid hemorrhage

  • August 21, 2026

Neuroprognostication after cardiac arrest: time-anchored reassessment and uncertainty around zero false positives